# GLP-1 Drugs and ERCP Complications: A TriNetX Cohort of 21,818 | This GLP A matched TriNetX analysis of 21,818 ERCP patients found every 30-day complication roughly halved with GLP-1 exposure | why uniform improvement signals selection, not effect. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/when-a-drug-improves-everything Updated: 2026-09-18 Published: 2026-09-17 [← Research](https://thisglp.com/research) Evidence # GLP-1 Drugs and ERCP Complications: A TriNetX Cohort of 21,818 Pancreatitis, bleeding, sepsis, stricture, cholangitis, repeat procedures: every outcome after ERCP improved by about the same amount with GLP-1 exposure. No drug does that. [This GLP Editorial Team](https://thisglp.com/about)September 20266 min readUpdated September 2026 Risk ratios, 30 days after the procedure · acute pancreatitis · 0.47 · GI bleeding · 0.49 · sepsis · 0.51 · biliary stricture · 0.52 · repeat procedure · 0.53 · cholangitis · 0.56 · Everything improved by about half. That is the problem. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - A matched analysis of 21,818 patients compared 30-day outcomes after ERCP, a bile duct procedure, by prior GLP-1 exposure. - Every major complication was roughly halved: pancreatitis 0.47, GI bleeding 0.49, sepsis 0.51, biliary stricture 0.52, repeat procedure 0.53, cholangitis 0.56. - Those outcomes have unrelated mechanisms. A drug producing all six effects at once is implausible. - ERCP is performed urgently in unstable patients and electively in stable ones, and people on a maintenance prescription are disproportionately the latter. ERCP threads an endoscope into the bile duct, and its best-known complication is pancreatitis — which makes a drug associated with fewer cases worth examining, given the long-running pancreatitis question covered in [the pancreatitis evidence](https://thisglp.com/research/do-glp1-drugs-cause-pancreatitis). This analysis reports exactly that, and then keeps going [\[1\]](https://thisglp.com/research/when-a-drug-improves-everything#ref-1). Acute pancreatitis came in at a risk ratio of 0.47 (95% CI 0.43–0.51). Cholangitis 0.56 (95% CI 0.50–0.62). Sepsis 0.51 (95% CI 0.46–0.57). Gastrointestinal bleeding 0.49. Biliary stricture 0.52. Repeat ERCP 0.53. Every major 30-day outcome the study measured was approximately halved. A drug that improves everything is measuring the patient These complications have nothing mechanistically in common. Post-procedure pancreatitis is about duct irritation and enzyme activation; bleeding is about sphincterotomy and clotting; sepsis is about infection and drainage; biliary stricture is an anatomical outcome that develops over weeks. No metabolic drug has six separate routes to halving all of them. When every outcome moves by the same amount, the thing being measured is usually the patient rather than the treatment. The likeliest explanation is visible in how the procedure is used. ERCP is done urgently in people who are acutely unwell with obstructed, infected bile ducts, and electively in stable outpatients with stones or strictures. Someone on an ongoing GLP-1 prescription is disproportionately in the second group: well enough to be on maintenance medication, engaged with care, scheduled rather than admitted. Urgency of indication is not something propensity matching on recorded covariates can capture. That is not a reason to dismiss the paper so much as to read it as a description of who is taking these drugs. The same signature — uniform improvement across outcomes with unrelated mechanisms — is what makes the mortality figures in [the intracranial pressure meta-analysis](https://thisglp.com/research/do-glp1-drugs-help-intracranial-hypertension) implausible, and it is why the negative-control approach used in [the FLOW subgroup analysis](https://thisglp.com/research/twenty-two-thirteen-seventeen) and elsewhere matters so much in claims research. If there is a real effect here it is most likely on pancreatitis specifically, where a mechanism exists and where the concern started. Establishing it would need a design that separates elective from urgent procedures, or a randomized comparison — and 21,818 matched patients, however well balanced on paper, cannot substitute for either. The general difficulty of reading procedure outcomes in this literature runs through [the thrombectomy cohort](https://thisglp.com/research/do-glp1-drugs-cause-aspiration-pneumonia). ## Frequently asked Do these drugs make bile duct procedures safer? The study reports every complication roughly halved, which is implausible as a drug effect because those complications have unrelated mechanisms. It more likely reflects which patients were on a maintenance prescription. Why is uniform improvement suspicious? Pancreatitis, bleeding, sepsis and stricture arise through completely different processes. A single metabolic drug halving all of them at once would require several unconnected mechanisms. Is any part of it likely real? Possibly the pancreatitis finding, where a plausible mechanism exists. Establishing it would need a design separating elective from urgent procedures, which this analysis does not do. ## Sources 1. \[1\] Kazi MAI, Khan J, Mufarrih SM, Widmer J, Al-Sabban A, Irani SS, Baron TH (2026). Protective Impact of GLP-1 Therapy on Post-ERCP Outcomes: A TriNetX Retrospective Cohort Analysis Journal of Clinical Gastroenterology. [PMID 42084951](https://pubmed.ncbi.nlm.nih.gov/42084951/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes)